Table 2. Phase 3 Trials Included in the Meta-analysisa.
| Phase 3 trials included | Median follow-up ≥24 mo | Source |
|---|---|---|
| Non–small cell lung cancer | ||
| CheckMate 017/057 | Yes | Borghaei et al,6 2021 |
| OAK | Yes | Mazieres et al,58 2021 |
| KEYNOTE-010 | Yes | Herbst et al,59 2021 |
| KEYNOTE-042 | No | Mok et al,60 2019 |
| IMpower110 | Yes | Jassem et al,61 2021 |
| CheckMate 227 | Yes | Hellmann et al,21 2019 |
| IMpower132 | Yes | Nishio et al,62 2021 |
| Melanoma | ||
| CA184-024 | Yes | Maio et al,12 2015 |
| CheckMate 066 | Yes | Robert et al,63 2020 |
| CheckMate 037 | Yes | Larkin et al,64 2018 |
| Urothelial carcinoma | ||
| KEYNOTE-045 | Yes | Fradet et al,5 2019 |
| IMvigor211 | Yes | van der Heijden et al,65 2021 |
| KEYNOTE-361 | Yes | Powles et al,66 2021 |
a
The overall survival Kaplan-Meier curves for the intention-to-treat population in all trials met the piecewise regression criteria.